

# Sang-We Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7691411/publications.pdf>

Version: 2024-02-01

157  
papers

7,657  
citations

87888

38  
h-index

56724

83  
g-index

161  
all docs

161  
docs citations

161  
times ranked

7018  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. <i>Cancer Research and Treatment</i> , 2023, 55, 83-93.	3.0	2
2	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 74-89.	9.4	133
3	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	1.1	173
4	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 423-433.	1.1	89
5	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296.	7.0	14
6	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). <i>Lung Cancer</i> , 2022, 166, 107-113.	2.0	3
7	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	1.1	43
8	The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study. <i>Cancer Medicine</i> , 2022, 11, 705-714.	2.8	1
9	Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON. <i>Journal of Clinical Oncology</i> , 2022, 40, 9035-9035.	1.6	0
10	Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 107-107.	1.6	6
11	Phase 3 trial of lorlatinib in treatment-naïve patients (Pts) with ALK-positive advanced non-small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses. <i>Journal of Clinical Oncology</i> , 2022, 40, 9070-9070.	1.6	5
12	A study of senaparib in combination with temozolomide for the treatment of patients with advanced solid tumors and extensive-stage small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3102-3102.	1.6	1
13	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations. <i>Journal of Clinical Oncology</i> , 2022, 40, 9017-9017.	1.6	9
14	Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study. <i>Cancer Research</i> , 2022, 82, CT016-CT016.	0.9	2
15	Abstract CT558: Capmatinib vs docetaxel as second- or third-line therapy in patients with locally advanced or metastatic MET-ex14-mutated NSCLC: The GeoMETry-III trial. <i>Cancer Research</i> , 2022, 82, CT558-CT558.	0.9	0
16	A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naïve patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 383-390.	6.4	54
17	A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 713-720.	6.4	13
18	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2459-2469.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 841-850.	2.2	2
20	Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 148, 202-210.	2.8	9
21	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9007-9007.	1.6	24
22	Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9071-9071.	1.6	3
23	Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9515-9515.	1.6	22
24	CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9134-TPS9134.	1.6	8
25	Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9047-9047.	1.6	28
26	Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9014-9014.	1.6	23
27	Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 3197-3204.	2.8	10
28	Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9006-9006.	1.6	55
29	Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. <i>BMC Cancer</i> , 2021, 21, 731.	2.6	4
30	The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. <i>Biomedicines</i> , 2021, 9, 665.	3.2	2
31	Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study. <i>Translational Lung Cancer Research</i> , 2021, 10, 2551-2561.	2.8	12
32	Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study. <i>Cancer Research</i> , 2021, 81, CT163-CT163.	0.9	8
33	Abstract 663: Longitudinal AXL assessment of circulating tumor cells (CTCs) and its clinical implication in the patients with EGFR mutated non-small cell lung cancer (NSCLC)., 2021, , .		0
34	Amivantamab in EGFR Exon 20 Insertion-“Mutated Non-“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	1.6	320
35	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100224.	1.1	6
36	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100206.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Integrin $\alpha 3 \beta 1$ Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	1
38	Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 19596.	3.3	5
39	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, e214761.	7.1	160
40	A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. <i>Future Oncology</i> , 2021, 17, 4827-4835.	2.4	1
41	Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis. <i>Current Medical Research and Opinion</i> , 2020, 36, 477-482.	1.9	9
42	Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor. <i>Thoracic Cancer</i> , 2020, 11, 436-442.	1.9	8
43	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	10.7	303
44	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 538-547.	1.6	221
45	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 404-415.	1.1	102
46	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 373-380.	4.1	95
47	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. <i>Cancers</i> , 2020, 12, 2658.	3.7	10
48	Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2020, 9, 1776058.	4.6	19
49	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overloc 169 8. 1132-1143.	10.7	169
50	Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3025-3036.	2.5	14
51	Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study. <i>Targeted Oncology</i> , 2020, 15, 75-84.	3.6	13
52	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 373-386.	10.7	300
53	Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis. <i>PLoS ONE</i> , 2020, 15, e0231546.	2.5	9
54	Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9500-9500.	1.6	42

#	ARTICLE	IF	CITATIONS
55	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9512-9512.	1.6	54
56	Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9574-9574.	1.6	4
57	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9601-9601.	1.6	1
58	Osimertinib as adjuvant therapy in patients (pts) with stage IB-III A EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA5-LBA5.	1.6	56
59	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. <i>Cancer Research and Treatment</i> , 2020, 52, 284-291.	3.0	4
60	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 1112-1119.	3.0	10
61	A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9636-TPS9636.	1.6	2
62	Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 2878-2894.	1.4	6
63	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014.	2.4	42
64	Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center. <i>PLoS ONE</i> , 2019, 14, e0221065.	2.5	11
65	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1681-1690.	10.7	92
66	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	1.1	69
67	Symptom experiences and health-related quality of life among non-small cell lung cancer patients participating in clinical trials. <i>Journal of Clinical Nursing</i> , 2019, 28, 2111-2123.	3.0	13
68	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 437-446.	10.7	192
69	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1255-1265.	1.1	59
70	Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis. <i>Translational Oncology</i> , 2019, 12, 852-858.	3.7	14
71	Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1099-1109.	2.0	6
72	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579.	2.5	31

#	ARTICLE	IF	CITATIONS
73	Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. <i>PLoS ONE</i> , 2019, 14, e0224379.	2.5	12
74	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, e407-e412.	2.6	12
75	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9009-9009.	1.6	74
76	Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 119-127.	3.0	23
77	Lazertinib, a 3 <sup>rd</sup> generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9037-9037.	1.6	2
78	The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205. <i>American Journal of Cancer Research</i> , 2019, 9, 597-607.	1.4	14
79	Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations. <i>American Journal of Cancer Research</i> , 2019, 9, 1708-1721.	1.4	2
80	Prognosis of multi-level N2+ positive non-small cell lung cancer according to lymph node staging using endobronchial ultrasound+transbronchial biopsy. <i>Thoracic Cancer</i> , 2018, 9, 684-692.	1.9	5
81	Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS. <i>Translational Oncology</i> , 2018, 11, 268-274.	3.7	16
82	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 576-584.	1.1	62
83	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. <i>Lung Cancer</i> , 2018, 119, 36-41.	2.0	7
84	Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. <i>Oncolmmunology</i> , 2018, 7, e1375642.	4.6	83
85	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	7
86	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 122, 234-242.	2.0	22
87	Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation+positive Cancer. <i>Radiology</i> , 2018, 289, 227-237.	7.3	19
88	Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018, 109, 2852-2862.	3.9	15
89	Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9008-9008.	1.6	47
90	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9033-9033.	1.6	2



#	ARTICLE	IF	CITATIONS
91	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-â€‘small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.. Journal of Clinical Oncology, 2018, 36, 9061-9061.	1.6	18
92	Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR</i>-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9094-9094.	1.6	10
93	Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.. Journal of Clinical Oncology, 2018, 36, TPS9117-TPS9117.	1.6	1
94	Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.. Journal of Clinical Oncology, 2018, 36, 169-169.	1.6	5
95	HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. BMB Reports, 2018, 51, 660-665.	2.4	14
96	The role of FDG-PET during osimertinib treatment to predict the responsiveness of tumor early in patients with stage IV non-small cell lung cancer: A pilot study.. Journal of Clinical Oncology, 2018, 36, e21150-e21150.	1.6	0
97	Osimertinib in Pretreated T790M-Positive Advanced Non-â€‘Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 2017, 35, 1288-1296.	1.6	470
98	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clinical Cancer Research, 2017, 23, 5406-5415.	7.0	29
99	HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. Cancer Letters, 2017, 411, 19-26.	7.2	21
100	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine, the, 2017, 5, 891-902.	10.7	92
101	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-â€‘Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, 1357-1367.	1.1	144
102	The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer. Cancer Letters, 2017, 406, 47-53.	7.2	27
103	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-â€‘Positive Non-â€‘Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 2490-2498.	1.6	506
104	Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). Journal of Thoracic Disease, 2017, 9, 3525-3528.	1.4	0
105	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. Journal of Clinical Oncology, 2017, 35, 2006-2006.	1.6	17
106	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. Journal of Clinical Oncology, 2017, 35, 2020-2020.	1.6	63
107	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. Journal of Clinical Oncology, 2017, 35, 2069-2069.	1.6	12
108	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9036-9036.	1.6	10

#	ARTICLE	IF	CITATIONS
109	Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.. Journal of Clinical Oncology, 2017, 35, 9085-9085.	1.6	7
110	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.. Journal of Clinical Oncology, 2017, 35, e20502-e20502.	1.6	3
111	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.. Journal of Clinical Oncology, 2017, 35, e20503-e20503.	1.6	3
112	Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.. Journal of Clinical Oncology, 2017, 35, e20504-e20504.	1.6	9
113	A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (&lt;i>EGFR&lt;/i>)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR&lt;i>Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2017, 49, 10-19.	3.0	35
114	Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations. Annals of Translational Medicine, 2017, 5, 11-11.	1.7	1
115	Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. Journal of Clinical Oncology, 2017, 35, 92-92.	1.6	0
116	Comprehensive outcomes of on&lt;i>and off&lt;/i>antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis. Journal of Medical Virology, 2016, 88, 1576-1586.	5.0	9
117	Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. BMC Cancer, 2016, 16, 417.	2.6	17
118	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncology, The, 2016, 17, 577-589.	10.7	950
119	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Investigational New Drugs, 2016, 34, 625-635.	2.6	52
120	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non&lt;i>Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. Journal of Thoracic Oncology, 2016, 11, 370-379.	1.1	21
121	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer, 2016, 93, 1-8.	2.0	13
122	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemotherapy and Pharmacology, 2016, 77, 767-776.	2.3	118
123	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation&lt;i>Positive Non&lt;i>Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 305.	7.1	201
124	The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib. Cancer Letters, 2016, 372, 75-81.	7.2	35
125	Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. Journal of Clinical Oncology, 2016, 34, 9002-9002.	1.6	59
126	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. Journal of Clinical Oncology, 2016, 34, 9007-9007.	1.6	25



#	ARTICLE	IF	CITATIONS
127	Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non-small-cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 9029-9029.	1.6	32
128	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. Journal of Clinical Oncology, 2016, 34, 9046-9046.	1.6	11
129	Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. BMC Cancer, 2015, 15, 763.	2.6	18
130	Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. Lung Cancer, 2015, 88, 139-146.	2.0	31
131	Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. Clinical Lung Cancer, 2015, 16, e83-e89.	2.6	40
132	Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-small-Cell Lung Cancer After Curative Resection. Clinical Lung Cancer, 2015, 16, e203-e212.	2.6	27
133	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology, The, 2015, 16, 990-998.	10.7	353
134	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-small-Cell Lung Cancer: KCSG-LU05-04. Journal of Clinical Oncology, 2015, 33, 2660-2666.	1.6	215
135	Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma. Clinical Cancer Research, 2015, 21, 2613-2623.	7.0	16
136	Bone metastasis in pulmonary sclerosing hemangioma. Korean Journal of Internal Medicine, 2015, 30, 928-930.	1.7	23
137	Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-small Cell Lung Cancer Harboring Wild-type EGFR. Oncologist, 2014, 19, 702-703.	3.7	11
138	Outcomes and prognostic factors of patients with lung cancer and pneumonia-induced respiratory failure in a medical intensive care unit: A single-center study. Journal of Critical Care, 2014, 29, 414-419.	2.2	9
139	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CChelN).. Journal of Clinical Oncology, 2014, 32, 7500-7500.	1.6	5
140	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8009-8009.	1.6	81
141	Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.. Journal of Clinical Oncology, 2014, 32, 8044-8044.	1.6	9
142	Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer. Radiation Oncology Journal, 2014, 32, 70.	1.5	10
143	A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy. Cancer Research and Treatment, 2014, 46, 19-26.	3.0	9
144	Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 6743-51.	0.5	8

#	ARTICLE	IF	CITATIONS
145	MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in <i>KRAS</i>-mutant advanced nonâ€“small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8029-8029.	1.6	15
146	Paclitaxel/carboplatin (PC) intercalated with gefitinib or paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC) in selected population who were smoker or wild-type EGFR: Randomized phase II study.. Journal of Clinical Oncology, 2013, 31, e19079-e19079.	1.6	0
147	Massive Hemoptysis Cases Intubated with the UniventÂ® Bronchial Blocker for Lung Protection. Tuberculosis and Respiratory Diseases, 2012, 72, 212.	1.8	0
148	Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, 7004-7004.	1.6	2
149	Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7543-7543.	1.6	28
150	Phase Ib study of oral PPARÎ³ agonist efatutazone (CS-7017) in combination with erlotinib in Korean patients with metastatic or unresectable locally advanced non-small cell lung cancer (NSCLC) who progressed after first-line therapy.. Journal of Clinical Oncology, 2012, 30, e18052-e18052.	1.6	1
151	ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (<i>EGFR</i>) mutation-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, TPS7614-TPS7614.	1.6	13
152	Renal Parenchymal Malakoplakia Presenting with Abscesses and Hepatic Extension Misdiagnosed as a Malignant Tumor: A Case Report. Korean Journal of Medicine, 2012, 82, 764.	0.3	2
153	Short Course Adjuvant Chemotherapy for Localized Diffuse Large B-Cell Lymphoma After Complete Resection.. Blood, 2010, 116, 2824-2824.	1.4	0
154	PROGNOSTIC SIGNIFICANCE of CD68 EXPRESSION for Korean PATIENTS with HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3888-3888.	1.4	1
155	Initial Cytreoreductive Treatment with Thalidomide Plus Bolus Vincristine/Doxorubicin and Reduced Dexamethasone (T-bVAd) Followed by Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma.. Blood, 2007, 110, 5094-5094.	1.4	0
156	Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer. Lung Cancer, 2003, 41, 221-226.	2.0	13
157	Murine Bone Marrow Stromal Cells: Implications for their Use in Gene Modified Cell Therapy. Leukemia and Lymphoma, 2003, 44, 1973-1978.	1.3	5